Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FD4RA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $1,892.90 to DMS Pharmaceutical Group Inc. for NUCALA 100 mg/ml auto-injector on October 29, 2025, with completion targeted for October 30, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order will be fulfilled at the company's Park Ridge facility and represents part of the company's broader pharmaceutical supply operations supporting the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide pharmaceutical and medical consumable support to military healthcare facilities worldwide. The parent contract, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a critical regional prime vendor contractor capable of supplying branded and generic prescription drugs, biologics, over-the-counter medications, and specialized medical products to support Department of Defense healthcare operations globally. NUCALA, an immunosuppressant biologic agent, aligns with the company's established product portfolio of specialty pharmaceuticals delivered through the PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DB26FD4RA?
SPE2DB26FD4RA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FD4RA worth?
The government has obligated $1,893 on SPE2DB26FD4RA.
Is contract SPE2DB26FD4RA an order under another contract?
Yes. SPE2DB26FD4RA is a delivery order under SPE2DB20D9214, an indefinite delivery contract.
Was contract SPE2DB26FD4RA competed?
The extent of competition for SPE2DB26FD4RA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award